Soil partice-size distribution. by Yonggang Huang (223155)

Subjects:

Group-based descriptive statistics and effect sizes. by Murat Tutar (22250461)

Subjects:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

“…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization by figshare admin karger (2628495)

“…This study investigated clinical characteristics and outcomes associated with longitudinal decreases in LV size in this population. Methods: We analyzed echocardiographic data from 6,232 adults with normal baseline left ventricular end-diastolic diameter (LVEDD), with a mean interval of 4.8 years between baseline and follow-up echocardiograms. …”

Comparison of the Non-healed but Improved DUs Based on Initial Wound Area Size in 2022 vs. 2023. by Heba Tallah Mohammed (2822432)

Subjects:

Comparison of the Non-healed but Improved PIs Based on Initial Wound Area Size in 2022 vs. 2023. by Heba Tallah Mohammed (2822432)

Subjects:

JP4-039 decreases mitochondrial ROS in human coronary artery endothelial cells <i>in vitro.</i> by Rayane Brinck Teixeira (6676529)

Enrichment analysis of genes from the significant MS module. by Lai Jiang (2401513)

Subjects:

Transition probabilities and class sizes for three-step LTA model (N = 432). by Carolin Oetzmann (11397968)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Overview of the WeARTolerance program. by Ana Beato (20489933)

Subjects:

Particle size distribution curve. by Quan Shen (37564)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects: